Serum  ||| S:0 E:6 ||| NNP
HIF-1alpha  ||| S:6 E:17 ||| NNP
and  ||| S:17 E:21 ||| CC
VEGF  ||| S:21 E:26 ||| NNP
levels  ||| S:26 E:33 ||| NNS
pre-  ||| S:33 E:38 ||| JJ
and  ||| S:38 E:42 ||| CC
post-TACE  ||| S:42 E:52 ||| JJ
in  ||| S:52 E:55 ||| IN
patients  ||| S:55 E:64 ||| NNS
with  ||| S:64 E:69 ||| IN
primary  ||| S:69 E:77 ||| JJ
liver  ||| S:77 E:83 ||| NN
cancer  ||| S:83 E:90 ||| NN
To  ||| S:90 E:93 ||| TO
investigate  ||| S:93 E:105 ||| VB
the  ||| S:105 E:109 ||| DT
expression  ||| S:109 E:120 ||| NN
levels  ||| S:120 E:127 ||| NNS
of  ||| S:127 E:130 ||| IN
serum  ||| S:130 E:136 ||| JJ
hypoxia  ||| S:136 E:144 ||| JJ
inducible  ||| S:144 E:154 ||| JJ
factor  ||| S:154 E:161 ||| NN
1  ||| S:161 E:163 ||| CD
alpha  ||| S:163 E:169 ||| NNS
( ||| S:169 E:170 ||| -LRB-
HIF-1alpha ||| S:170 E:180 ||| NNP
)  ||| S:180 E:182 ||| -RRB-
and  ||| S:182 E:186 ||| CC
vascular  ||| S:186 E:195 ||| JJ
endothelial  ||| S:195 E:207 ||| JJ
growth  ||| S:207 E:214 ||| NN
factor  ||| S:214 E:221 ||| NN
( ||| S:221 E:222 ||| -LRB-
VEGF ||| S:222 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
pre-  ||| S:228 E:233 ||| JJ
and  ||| S:233 E:237 ||| CC
post-transcatheter  ||| S:237 E:256 ||| JJ
arterial  ||| S:256 E:265 ||| JJ
chemoembolization  ||| S:265 E:283 ||| NNS
( ||| S:283 E:284 ||| -LRB-
TACE ||| S:284 E:288 ||| NNP
)  ||| S:288 E:290 ||| -RRB-
in  ||| S:290 E:293 ||| IN
patients  ||| S:293 E:302 ||| NNS
with  ||| S:302 E:307 ||| IN
primary  ||| S:307 E:315 ||| JJ
liver  ||| S:315 E:321 ||| NN
cancer  ||| S:321 E:328 ||| NN
( ||| S:328 E:329 ||| -LRB-
PLC ||| S:329 E:332 ||| NNP
) ||| S:332 E:333 ||| -RRB-
,  ||| S:333 E:335 ||| ,
and  ||| S:335 E:339 ||| CC
correlations  ||| S:339 E:352 ||| NN
between  ||| S:352 E:360 ||| IN
prognosis  ||| S:360 E:370 ||| JJ
factors  ||| S:370 E:378 ||| NNS
and  ||| S:378 E:382 ||| CC
serum  ||| S:382 E:388 ||| JJ
HIF-1alpha  ||| S:388 E:399 ||| NN
as  ||| S:399 E:402 ||| IN
well  ||| S:402 E:407 ||| RB
asVEGF  ||| S:407 E:414 ||| JJ
levels ||| S:414 E:420 ||| NNS
.  ||| S:420 E:422 ||| .
Forty  ||| S:422 E:428 ||| JJ
consecutive  ||| S:428 E:440 ||| JJ
patients  ||| S:440 E:449 ||| NNS
fulfilling  ||| S:449 E:460 ||| VBG
diagnostic  ||| S:460 E:471 ||| JJ
criteria  ||| S:471 E:480 ||| NNS
for  ||| S:480 E:484 ||| IN
PLC  ||| S:484 E:488 ||| NNP
undergoing  ||| S:488 E:499 ||| VBG
TACE  ||| S:499 E:504 ||| NNP
from  ||| S:504 E:509 ||| IN
March  ||| S:509 E:515 ||| NNP
2008  ||| S:515 E:520 ||| CD
to  ||| S:520 E:523 ||| TO
May  ||| S:523 E:527 ||| NNP
2009  ||| S:527 E:532 ||| CD
were  ||| S:532 E:537 ||| VBD
enrolled  ||| S:537 E:546 ||| VBN
into  ||| S:546 E:551 ||| IN
the  ||| S:551 E:555 ||| DT
study ||| S:555 E:560 ||| NN
.  ||| S:560 E:562 ||| .
The  ||| S:562 E:566 ||| DT
serum  ||| S:566 E:572 ||| JJ
HIF-1alpha  ||| S:572 E:583 ||| NN
and  ||| S:583 E:587 ||| CC
VEGF  ||| S:587 E:592 ||| NNP
levels  ||| S:592 E:599 ||| NNS
of  ||| S:599 E:602 ||| IN
PLC  ||| S:602 E:606 ||| NNP
patients  ||| S:606 E:615 ||| NNS
pre-  ||| S:615 E:620 ||| JJ
and  ||| S:620 E:624 ||| CC
1  ||| S:624 E:626 ||| CD
day ||| S:626 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
1  ||| S:631 E:633 ||| CD
week ||| S:633 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
1  ||| S:639 E:641 ||| CD
month  ||| S:641 E:647 ||| NN
post-TACE  ||| S:647 E:657 ||| NN
were  ||| S:657 E:662 ||| VBD
analyzed  ||| S:662 E:671 ||| VBN
using  ||| S:671 E:677 ||| VBG
ELISA ||| S:677 E:682 ||| NNP
,  ||| S:682 E:684 ||| ,
and  ||| S:684 E:688 ||| CC
compared  ||| S:688 E:697 ||| VBN
with  ||| S:697 E:702 ||| IN
that  ||| S:702 E:707 ||| DT
of  ||| S:707 E:710 ||| IN
20  ||| S:710 E:713 ||| CD
healthy  ||| S:713 E:721 ||| JJ
volunteers ||| S:721 E:731 ||| NNS
.  ||| S:731 E:733 ||| .
Patients  ||| S:733 E:742 ||| NNS
were  ||| S:742 E:747 ||| VBD
divided  ||| S:747 E:755 ||| VBN
into  ||| S:755 E:760 ||| IN
complete  ||| S:760 E:769 ||| JJ
response  ||| S:769 E:778 ||| NN
( ||| S:778 E:779 ||| -LRB-
CR ||| S:779 E:781 ||| NNP
)  ||| S:781 E:783 ||| -RRB-
and  ||| S:783 E:787 ||| CC
partial  ||| S:787 E:795 ||| JJ
response  ||| S:795 E:804 ||| NN
( ||| S:804 E:805 ||| -LRB-
PR ||| S:805 E:807 ||| NNP
) ||| S:807 E:808 ||| -RRB-
,  ||| S:808 E:810 ||| ,
stable  ||| S:810 E:817 ||| JJ
disease  ||| S:817 E:825 ||| NN
( ||| S:825 E:826 ||| -LRB-
SD ||| S:826 E:828 ||| NNP
) ||| S:828 E:829 ||| -RRB-
,  ||| S:829 E:831 ||| ,
progressive  ||| S:831 E:843 ||| JJ
disease  ||| S:843 E:851 ||| NN
( ||| S:851 E:852 ||| -LRB-
PD ||| S:852 E:854 ||| NNP
)  ||| S:854 E:856 ||| -RRB-
groups  ||| S:856 E:863 ||| NNS
according  ||| S:863 E:873 ||| VBG
to  ||| S:873 E:876 ||| TO
the  ||| S:876 E:880 ||| DT
therapeutic  ||| S:880 E:892 ||| JJ
efficacy ||| S:892 E:900 ||| NN
.  ||| S:900 E:902 ||| .
Pearson  ||| S:902 E:910 ||| NNP
correlation  ||| S:910 E:922 ||| NN
was  ||| S:922 E:926 ||| VBD
used  ||| S:926 E:931 ||| VBN
to  ||| S:931 E:934 ||| TO
analyze  ||| S:934 E:942 ||| VB
the  ||| S:942 E:946 ||| DT
correlation  ||| S:946 E:958 ||| NN
between  ||| S:958 E:966 ||| IN
different  ||| S:966 E:976 ||| JJ
clinical  ||| S:976 E:985 ||| JJ
variables  ||| S:985 E:995 ||| NNS
and  ||| S:995 E:999 ||| CC
serum  ||| S:999 E:1005 ||| JJ
HIF-  ||| S:1005 E:1010 ||| JJ
1alpha  ||| S:1010 E:1017 ||| NN
and  ||| S:1017 E:1021 ||| CC
VEGF  ||| S:1021 E:1026 ||| NNP
levels  ||| S:1026 E:1033 ||| NNS
before  ||| S:1033 E:1040 ||| IN
TACE ||| S:1040 E:1044 ||| NNP
,  ||| S:1044 E:1046 ||| ,
and  ||| S:1046 E:1050 ||| CC
correlation  ||| S:1050 E:1062 ||| NN
between  ||| S:1062 E:1070 ||| IN
serum  ||| S:1070 E:1076 ||| JJ
HIF-1alpha  ||| S:1076 E:1087 ||| NN
and  ||| S:1087 E:1091 ||| CC
VEGF  ||| S:1091 E:1096 ||| NNP
levels  ||| S:1096 E:1103 ||| NNS
was  ||| S:1103 E:1107 ||| VBD
also  ||| S:1107 E:1112 ||| RB
evaluated ||| S:1112 E:1121 ||| VBN
.  ||| S:1121 E:1123 ||| .
The  ||| S:1123 E:1127 ||| DT
expression  ||| S:1127 E:1138 ||| NN
levels  ||| S:1138 E:1145 ||| NNS
of  ||| S:1145 E:1148 ||| IN
serum  ||| S:1148 E:1154 ||| JJ
HIF-1alpha  ||| S:1154 E:1165 ||| NN
and  ||| S:1165 E:1169 ||| CC
VEGF  ||| S:1169 E:1174 ||| NNP
in  ||| S:1174 E:1177 ||| IN
PLC  ||| S:1177 E:1181 ||| NNP
patients  ||| S:1181 E:1190 ||| NNS
were  ||| S:1190 E:1195 ||| VBD
154.94  ||| S:1195 E:1202 ||| CD
+ ||| S:1202 E:1203 ||| CD
/ ||| S:1203 E:1204 ||| CD
-  ||| S:1204 E:1206 ||| :
83.29  ||| S:1206 E:1212 ||| CD
and  ||| S:1212 E:1216 ||| CC
264.00  ||| S:1216 E:1223 ||| CD
+ ||| S:1223 E:1224 ||| CD
/ ||| S:1224 E:1225 ||| CD
-  ||| S:1225 E:1227 ||| :
148.10  ||| S:1227 E:1234 ||| CD
pg ||| S:1234 E:1236 ||| CD
/ ||| S:1236 E:1237 ||| CD
mL  ||| S:1237 E:1240 ||| JJ
pre-TACE ||| S:1240 E:1248 ||| NN
,  ||| S:1248 E:1250 ||| ,
and  ||| S:1250 E:1254 ||| CC
both  ||| S:1254 E:1259 ||| DT
of  ||| S:1259 E:1262 ||| IN
them  ||| S:1262 E:1267 ||| PRP
were  ||| S:1267 E:1272 ||| VBD
significantly  ||| S:1272 E:1286 ||| RB
higher  ||| S:1286 E:1293 ||| JJR
than  ||| S:1293 E:1298 ||| IN
those  ||| S:1298 E:1304 ||| DT
in  ||| S:1304 E:1307 ||| IN
control  ||| S:1307 E:1315 ||| NN
group  ||| S:1315 E:1321 ||| NN
( ||| S:1321 E:1322 ||| -LRB-
23.84  ||| S:1322 E:1328 ||| NNP
+ ||| S:1328 E:1329 ||| NNP
/ ||| S:1329 E:1330 ||| NNP
-  ||| S:1330 E:1332 ||| :
8.15  ||| S:1332 E:1337 ||| CD
and  ||| S:1337 E:1341 ||| CC
69.78  ||| S:1341 E:1347 ||| CD
+ ||| S:1347 E:1348 ||| CD
/ ||| S:1348 E:1349 ||| CD
-  ||| S:1349 E:1351 ||| :
21.42  ||| S:1351 E:1357 ||| CD
pg ||| S:1357 E:1359 ||| CD
/ ||| S:1359 E:1360 ||| CD
mL ||| S:1360 E:1362 ||| NN
,  ||| S:1362 E:1364 ||| ,
all  ||| S:1364 E:1368 ||| DT
P  ||| S:1368 E:1369 ||| NN
< ||| S:1369 E:1370 ||| SYM
0.01 ||| S:1370 E:1374 ||| CD
) ||| S:1374 E:1375 ||| -RRB-
.  ||| S:1375 E:1377 ||| .
One  ||| S:1377 E:1381 ||| CD
day  ||| S:1381 E:1385 ||| NN
after  ||| S:1385 E:1391 ||| IN
TACE ||| S:1391 E:1395 ||| NNP
,  ||| S:1395 E:1397 ||| ,
both  ||| S:1397 E:1402 ||| DT
serum  ||| S:1402 E:1408 ||| JJ
HIF-1alpha  ||| S:1408 E:1419 ||| NNP
( ||| S:1419 E:1420 ||| -LRB-
570.64  ||| S:1420 E:1427 ||| NNP
+ ||| S:1427 E:1428 ||| NNP
/ ||| S:1428 E:1429 ||| NNP
-  ||| S:1429 E:1431 ||| :
230.87  ||| S:1431 E:1438 ||| FW
pg ||| S:1438 E:1440 ||| FW
/ ||| S:1440 E:1441 ||| FW
mL ||| S:1441 E:1443 ||| FW
)  ||| S:1443 E:1445 ||| -RRB-
and  ||| S:1445 E:1449 ||| CC
VEGF  ||| S:1449 E:1454 ||| NNP
levels  ||| S:1454 E:1461 ||| NNS
( ||| S:1461 E:1462 ||| -LRB-
362.07  ||| S:1462 E:1469 ||| NNP
+ ||| S:1469 E:1470 ||| NNP
/ ||| S:1470 E:1471 ||| NNP
-  ||| S:1471 E:1473 ||| :
102.25  ||| S:1473 E:1480 ||| CD
pg ||| S:1480 E:1482 ||| CD
/ ||| S:1482 E:1483 ||| CD
mL ||| S:1483 E:1485 ||| NN
)  ||| S:1485 E:1487 ||| -RRB-
reached  ||| S:1487 E:1495 ||| VBD
the  ||| S:1495 E:1499 ||| DT
peak  ||| S:1499 E:1504 ||| NN
values  ||| S:1504 E:1511 ||| NNS
( ||| S:1511 E:1512 ||| -LRB-
all  ||| S:1512 E:1516 ||| DT
P  ||| S:1516 E:1517 ||| NN
< ||| S:1517 E:1518 ||| SYM
0.01 ||| S:1518 E:1522 ||| CD
) ||| S:1522 E:1523 ||| -RRB-
.  ||| S:1523 E:1525 ||| .
One  ||| S:1525 E:1529 ||| CD
week  ||| S:1529 E:1534 ||| NN
post-TACE ||| S:1534 E:1543 ||| NN
,  ||| S:1543 E:1545 ||| ,
expression  ||| S:1545 E:1556 ||| NN
levels  ||| S:1556 E:1563 ||| NNS
of  ||| S:1563 E:1566 ||| IN
them  ||| S:1566 E:1571 ||| PRP
were  ||| S:1571 E:1576 ||| VBD
decreased  ||| S:1576 E:1586 ||| VBN
( ||| S:1586 E:1587 ||| -LRB-
198.62  ||| S:1587 E:1594 ||| NNP
+ ||| S:1594 E:1595 ||| NNP
/ ||| S:1595 E:1596 ||| NNP
-  ||| S:1596 E:1598 ||| :
92.11  ||| S:1598 E:1604 ||| CD
and  ||| S:1604 E:1608 ||| CC
283.52  ||| S:1608 E:1615 ||| CD
+ ||| S:1615 E:1616 ||| CD
/ ||| S:1616 E:1617 ||| CD
-  ||| S:1617 E:1619 ||| :
145.46  ||| S:1619 E:1626 ||| FW
pg ||| S:1626 E:1628 ||| FW
/ ||| S:1628 E:1629 ||| FW
mL  ||| S:1629 E:1632 ||| FW
respectively ||| S:1632 E:1644 ||| FW
) ||| S:1644 E:1645 ||| -RRB-
,  ||| S:1645 E:1647 ||| ,
but  ||| S:1647 E:1651 ||| CC
still  ||| S:1651 E:1657 ||| RB
significantly  ||| S:1657 E:1671 ||| RB
higher  ||| S:1671 E:1678 ||| JJR
than  ||| S:1678 E:1683 ||| IN
those  ||| S:1683 E:1689 ||| DT
before  ||| S:1689 E:1696 ||| IN
TACE  ||| S:1696 E:1701 ||| NNP
( ||| S:1701 E:1702 ||| -LRB-
all  ||| S:1702 E:1706 ||| DT
P  ||| S:1706 E:1707 ||| NN
< ||| S:1707 E:1708 ||| SYM
0.01 ||| S:1708 E:1712 ||| CD
) ||| S:1712 E:1713 ||| -RRB-
.  ||| S:1713 E:1715 ||| .
The  ||| S:1715 E:1719 ||| DT
levels  ||| S:1719 E:1726 ||| NNS
of  ||| S:1726 E:1729 ||| IN
both  ||| S:1729 E:1734 ||| DT
HIF-1alpha  ||| S:1734 E:1745 ||| NNP
( ||| S:1745 E:1746 ||| -LRB-
133.96  ||| S:1746 E:1753 ||| NNP
+ ||| S:1753 E:1754 ||| NNP
/ ||| S:1754 E:1755 ||| NNP
-  ||| S:1755 E:1757 ||| :
57.02  ||| S:1757 E:1763 ||| FW
vs.  ||| S:1763 E:1767 ||| FW
255.74  ||| S:1767 E:1774 ||| FW
+ ||| S:1774 E:1775 ||| FW
/ ||| S:1775 E:1776 ||| FW
-  ||| S:1776 E:1778 ||| :
123.44  ||| S:1778 E:1785 ||| FW
pg ||| S:1785 E:1787 ||| FW
/ ||| S:1787 E:1788 ||| FW
mL ||| S:1788 E:1790 ||| FW
)  ||| S:1790 E:1792 ||| -RRB-
and  ||| S:1792 E:1796 ||| CC
VEGF  ||| S:1796 E:1801 ||| NNP
( ||| S:1801 E:1802 ||| -LRB-
150.96  ||| S:1802 E:1809 ||| NNP
+ ||| S:1809 E:1810 ||| NNP
/ ||| S:1810 E:1811 ||| NNP
-  ||| S:1811 E:1813 ||| :
84.89  ||| S:1813 E:1819 ||| FW
vs.  ||| S:1819 E:1823 ||| FW
368.95  ||| S:1823 E:1830 ||| FW
+ ||| S:1830 E:1831 ||| FW
/ ||| S:1831 E:1832 ||| FW
-  ||| S:1832 E:1834 ||| :
161.90  ||| S:1834 E:1841 ||| FW
pg ||| S:1841 E:1843 ||| FW
/ ||| S:1843 E:1844 ||| FW
mL ||| S:1844 E:1846 ||| FW
)  ||| S:1846 E:1848 ||| -RRB-
in  ||| S:1848 E:1851 ||| IN
CR  ||| S:1851 E:1854 ||| NNP
group  ||| S:1854 E:1860 ||| NN
1  ||| S:1860 E:1862 ||| CD
month  ||| S:1862 E:1868 ||| NN
post-TACE  ||| S:1868 E:1878 ||| NN
were  ||| S:1878 E:1883 ||| VBD
significantly  ||| S:1883 E:1897 ||| RB
lower  ||| S:1897 E:1903 ||| JJR
than  ||| S:1903 E:1908 ||| IN
those  ||| S:1908 E:1914 ||| DT
in  ||| S:1914 E:1917 ||| IN
PR+SD+PD  ||| S:1917 E:1926 ||| CD
group  ||| S:1926 E:1932 ||| NN
( ||| S:1932 E:1933 ||| -LRB-
all  ||| S:1933 E:1937 ||| DT
P  ||| S:1937 E:1938 ||| NN
< ||| S:1938 E:1939 ||| SYM
0.01 ||| S:1939 E:1943 ||| CD
) ||| S:1943 E:1944 ||| -RRB-
.  ||| S:1944 E:1946 ||| .
The  ||| S:1946 E:1950 ||| DT
level  ||| S:1950 E:1956 ||| NN
of  ||| S:1956 E:1959 ||| IN
serum  ||| S:1959 E:1965 ||| JJ
HIF-1alpha  ||| S:1965 E:1976 ||| NN
was  ||| S:1976 E:1980 ||| VBD
positively  ||| S:1980 E:1991 ||| RB
correlated  ||| S:1991 E:2002 ||| VBN
with  ||| S:2002 E:2007 ||| IN
serum  ||| S:2007 E:2013 ||| JJ
VEGF  ||| S:2013 E:2018 ||| NNP
level  ||| S:2018 E:2024 ||| NN
( ||| S:2024 E:2025 ||| -LRB-
r=0.42 ||| S:2025 E:2031 ||| NNP
,  ||| S:2031 E:2033 ||| ,
P  ||| S:2033 E:2034 ||| NNP
< ||| S:2034 E:2035 ||| SYM
0.001 ||| S:2035 E:2040 ||| NNP
) ||| S:2040 E:2041 ||| -RRB-
.  ||| S:2041 E:2043 ||| .
Both  ||| S:2043 E:2048 ||| DT
serum  ||| S:2048 E:2054 ||| JJ
HIF-1alpha  ||| S:2054 E:2065 ||| NN
and  ||| S:2065 E:2069 ||| CC
VEGF  ||| S:2069 E:2074 ||| NNP
levels  ||| S:2074 E:2081 ||| NNS
were  ||| S:2081 E:2086 ||| VBD
observed  ||| S:2086 E:2095 ||| VBN
to  ||| S:2095 E:2098 ||| TO
be  ||| S:2098 E:2101 ||| VB
correlated  ||| S:2101 E:2112 ||| VBN
with  ||| S:2112 E:2117 ||| IN
portal  ||| S:2117 E:2124 ||| FW
vein  ||| S:2124 E:2129 ||| FW
tumor  ||| S:2129 E:2135 ||| FW
thrombi  ||| S:2135 E:2143 ||| FW
( ||| S:2143 E:2144 ||| -LRB-
P  ||| S:2144 E:2145 ||| NNP
< ||| S:2145 E:2146 ||| SYM
0.05 ||| S:2146 E:2150 ||| CD
)  ||| S:2150 E:2152 ||| -RRB-
and  ||| S:2152 E:2156 ||| CC
metastasis  ||| S:2156 E:2167 ||| NNS
( ||| S:2167 E:2168 ||| -LRB-
P  ||| S:2168 E:2169 ||| NNP
< ||| S:2169 E:2170 ||| SYM
0.05 ||| S:2170 E:2174 ||| CD
) ||| S:2174 E:2175 ||| -RRB-
.  ||| S:2175 E:2177 ||| .
The  ||| S:2177 E:2181 ||| DT
HIF-  ||| S:2181 E:2186 ||| JJ
1alpha  ||| S:2186 E:2193 ||| NN
and  ||| S:2193 E:2197 ||| CC
VEGF  ||| S:2197 E:2202 ||| NNP
might  ||| S:2202 E:2208 ||| MD
play  ||| S:2208 E:2213 ||| VB
an  ||| S:2213 E:2216 ||| DT
important  ||| S:2216 E:2226 ||| JJ
role  ||| S:2226 E:2231 ||| NN
in  ||| S:2231 E:2234 ||| IN
relapse  ||| S:2234 E:2242 ||| NN
of  ||| S:2242 E:2245 ||| IN
PLC ||| S:2245 E:2248 ||| NNP
.  ||| S:2248 E:2250 ||| .
They  ||| S:2250 E:2255 ||| PRP
might  ||| S:2255 E:2261 ||| MD
be  ||| S:2261 E:2264 ||| VB
considered  ||| S:2264 E:2275 ||| VBN
as  ||| S:2275 E:2278 ||| IN
predictors  ||| S:2278 E:2289 ||| NN
of  ||| S:2289 E:2292 ||| IN
the  ||| S:2292 E:2296 ||| DT
efficacy  ||| S:2296 E:2305 ||| JJ
ofTACE  ||| S:2305 E:2312 ||| JJ
and  ||| S:2312 E:2316 ||| CC
metastasis  ||| S:2316 E:2327 ||| NN
of  ||| S:2327 E:2330 ||| IN
PLC ||| S:2330 E:2333 ||| NNP
.  ||| S:2333 E:2335 ||| .
